Hostname: page-component-848d4c4894-xm8r8 Total loading time: 0 Render date: 2024-06-24T03:13:04.207Z Has data issue: false hasContentIssue false
  • English
  • Français

Monotherapy or Polytherapy for Epilepsy?

Published online by Cambridge University Press:  18 September 2015

Alan Guberman
Alan Guberman*
Affiliation:
Division of Neurology, Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa
*
Division of Neurology, Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Monotherapy has been promoted as the ideal in epilepsy treatment because of reduced side effects, absence of drug interactions, better compliance, lower cost and, in many cases, improved seizure control compared to polytherapy. The question of monotherapy vs. polytherapy has assumed increasing importance with the availability of multiple new antiepileptic drugs (AEDs), initially tested as add-on agents. The new drugs clobazam, lamotrigine, vigabatrin, gabapentin and topiramate, have also been shown to be effective as monotherapy. These data bring up the possibility of using them as first-line agents. However, a high percentage of patients with resistant epilepsy are treated with polytherapy, which probably benefits only a minority of them. The availability of multiple drugs with different mechanisms of action favours the possibility of "rational polytherapy", taking advantage of possible synergism, a yet unproven concept. This article reviews the theoretical advantages of monotherapy and monotherapy with traditional and newer AEDs.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue S4 , November 1998 , pp. S3 - S8
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

Shorvon, SD, Reynolds, EH.Reduction in polypharmacy for epilepsy. Brit Med J 1979; 2: 1023–1025.CrossRefGoogle ScholarPubMed
Schmidt, D.Reduction of two drug therapy in intractable epilepsy. Epilepsia 1983; 24: 368–376.CrossRefGoogle ScholarPubMed
Theodore, WH, Porter, RJ.Removal of sedative-hypnotic antiepileptics from the regimens of patients with intractable epilepsy. Ann Neurol 1983; 13: 320–324.CrossRefGoogle ScholarPubMed
Mattson, RH, Cramer, JACollins, JFet al.Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–151.CrossRefGoogle ScholarPubMed
Reynolds, EH, Shorvon, SD.Monotherapy or polytherapy for epilepsy. Epilepsia 1981; 22: 1–10.CrossRefGoogle ScholarPubMed
Bourgeois BFD. Pharmacologic interactions between valproate and other drugs. Am J Med M88; 84 (Suppl 1A): 29–33.Google Scholar
Lindout, D.Pharmacogenetics and drug interactions: role in antiepileptic drug-induced teratogenesis. Neurology 1992; 42 5: 43–47.Google Scholar
Shorvon, SD, Reynolds, EH.Unnecessary polypharmacy for epilepsy. Brit Med J 1977; 1: 1635–1637.CrossRefGoogle ScholarPubMed
Beghi, E, DeMascio, RSasanelli, Fet al.Adverse reactions to antiepileptic drugs: a multicentre survey or clinical practice. Epilepsia 1986; 27: 323–330.CrossRefGoogle Scholar
Bryant, AE III, Dreifuss, FE.Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465–469.CrossRefGoogle ScholarPubMed
Brodie, MJ, Yven, AWC.Lamotrigine substitution study: evidence for synergism with sodium valproate?. Epilepsy Res 1997; 26: 423–432.CrossRefGoogle ScholarPubMed
Lammers, MW, Hekster, YA, Keyser, A, et al.Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia 1995; 36: 440–446.CrossRefGoogle ScholarPubMed
Deckers, CLP, Hekster, YA, Keyser, A, et al.Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 1997; 38: 570–575.CrossRefGoogle ScholarPubMed
Morris, JC, Dodson, E, Hatlelid, M, et al.Phenytoin and carbamazepine alone and in combination: anticonvulsant and neurotoxic effects. Neurology 1987; 37: 1111–1118.CrossRefGoogle ScholarPubMed
Bourgeois, B, Beaumanoir, A, Blajev, B, et al.Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987; 28 (Suppl 2): S8–Sll.CrossRefGoogle ScholarPubMed
Mattson, RH, Cramer, JA, Collins, JF, et al.A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765–771.CrossRefGoogle ScholarPubMed
Richens, A, Davidson, DLW, Cartlidge, NF, et al.A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 37: 682–687.CrossRefGoogle Scholar
Heller, AJ, Chesterman, P, Elwes, RDC, et al.Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomized comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44–50.CrossRefGoogle ScholarPubMed
Seino, M.Acomment on the efficacy of valproate in the treatment of partial seizures. Epilepsia 1994; 35 (Suppl 5):S101–S104.CrossRefGoogle ScholarPubMed
Verity, CM, Hosking, G, Easter, DJ. A multicentre comparative trails of sodium valproate and carbamazepine in pediatric epilepsy. Develop Med Child Neurol 1995; 37: 97–108.CrossRefGoogle Scholar
De Silva, M, MacArdle, B, McGowan, M, et al.Randomized comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly-diagnosed childhood epilepsy. Lancet 1996; 347: 709–713.CrossRefGoogle ScholarPubMed
Beydoun, A, et al.Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration response design clinical trial. Neurology 1997; 48: 182–188.CrossRefGoogle ScholarPubMed
Christie, W, Krämer, G, Vigonius, V, et al.A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 451–460.CrossRefGoogle Scholar
Reunanen, M, Dam, M, Yven, AWC. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149–155.CrossRefGoogle ScholarPubMed
Brodie, MJ, Richens, A, Yven, AWC, et al.Double-blind comparison of lamotrigine and carbamazepine in newly-diagnosed epilepsy. Lancet 1995; 345: 476–479.CrossRefGoogle ScholarPubMed
Steiner, TJ, Yven, AWC.Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy. Epilepsia 1994; 35 (Suppl 8): S31.Google Scholar
Faught, E.Lamotrigine monotherapy in patients with refractory partial-onset seizures. In: Loiseau, P, ed. Lamotrigine—A Brighter Future. International Congress and Symposium Series #214. London: Royal Society of Medicine Press. 1996: 37–42.Google Scholar
Perucca, E.Add-on trial of lamotrigine followed by withdrawal of concomitant medication and stabilization on monotherapy. In: Loiseau, P, ed. Lamotrigine—A Brighter Future. International Congress and Symposium Series #214. London: Royal Society of Medicine Press. 1996: pp.23–30.Google Scholar
Chang, G, Vazquez, B, Gilliam, F, et al.Lamictal (lamotrigine) monotherapy as an effective treatment for partial seizures. Neurology 1997; 48 (Suppl): A335.Google Scholar
Dulac, O, Figueroa, D, Rey, E, et al.Monothérapie par le clobazam dans l’épilepsie de l’enfant. Presse Méd 1983; 12: 1067–1069.Google Scholar
Plouin, P, Jalin, C.EEG changes in epileptic children treated with clobazam as monotherapy. London: Royal Society of Medicine International Congress and Symposium: Series No. 74, 1985: 191–197.Google Scholar
The Canadian Clobazam Study Group for Childhood Epilepsy. Monotherapy clobazam vs. carbamazepine vs. phenytoin in childhood epilepsy: a double-blind randomized trial with 220 Canadian children. Can J Neurol Sci 1996; 23 (Suppl 1): S18.Google Scholar
Fisher, R, Kälviäinen, R, Tanganelli, P, et al.Newer antiepileptic drugs as monotherapy: data on vigabatrin. Neurology 1996; 47 (Suppl 1): S2–S5.CrossRefGoogle ScholarPubMed
Kälviäinen, R, Aikiä, M, Saukkonen, A, et al.Vigabatrin vs carbamazepine monotherapy in patients newly diagnosed with epilepsy: a randomized controlled study. Arch Neurol 1995; 42: 989–996.CrossRefGoogle Scholar
Tanganelli, P, Regesta, G.Vigabatrin vs. carbamazepine monotherapy in newly-diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res 1996; 25: 257–262.CrossRefGoogle ScholarPubMed
Brodie, MJ, Roy, KB. One drug or two? A double-blind comparison of adjuvant vigabatrin and valproate in carbamazepine-resistant epilepsy. Epilepsia 1996; 37 (Suppl 5): S170.Google Scholar
Krauuss, GL, Johnson, MA, Miller, NR. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614–618.CrossRefGoogle Scholar
Bergey, GK, Morris, HH, Rosenfeld, W, et al.Gabapentin monotherapy. I: an 8-day, double-blind, dose-controlled, multicentre study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology 1997; 49: 739–745.CrossRefGoogle ScholarPubMed
Beydoun, A, Fisher, J, Labar, DR, et al.Gabapentin monotherapy. II: A 26-week, double-blind, dose-controlled, multicentre study of conversion from polytherapy in out-patients with refractory complex partial or secondarily generalized seizures. Neurology 1997; 49: 746–752.CrossRefGoogle ScholarPubMed
Chadwick, D, Anhut, H, Murray, G, et al.Gabapentin (GBP; Neurontin ®) as monotherapy in newly-diagnosed patients with partial epilepsy: a fixed-dose comparison study vs. carbamazepine. Second European Congress of Epileptology, The Hague, September, 1996.Google Scholar
Sachdeo, RC, Reife, R, Pilar, L, et al.GTopiramate monotherapy for partial onset seizures. Epilepsia 1997; 38: 294–300.CrossRefGoogle ScholarPubMed